Clinical trials: Patients With Tumor
Cancer of the Liver
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00422877
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- American Regent, Inc.
Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
A phase II study of combination therapy of carboplatin -gemcitabine plus bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior…
- Trial name
- NCT00702975
- Testing
- Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Radboud University Medical Center
Non Small Cell Lung Cancer
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage…
- Trial name
- NCT03228277
- Testing
- Olmutinib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Konkuk University Medical Center
Neurofibromatosis 2, Meningioma
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
- Trial name
- NCT02831257
- Testing
- AZD2014
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer, Anemia
Effects of Preoperative Correction of Anemia With Intravenously Iron in Colorectal Cancer Patients.
The aim of the study is to examine the effects of anemia correction with intravenous administered iron on clinical outcomes and the immune response on the tumor in patients with planned colonic- or rectal cancer surgery.
- Conditions
- Colorectal Cancer, Anemia, Iron-deficiency
- Trial name
- NCT05221957
- Testing
- Iron(III)isomaltoside
- Volunteers
- 200 people
- Sponsor
- Zealand University Hospital
Advanced Solid Tumors Cancer
First-In-Human Study of KHN922 for Injection
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
- Trial name
- NCT07514975
- Testing
- KHN922 for injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Carcinoma, Renal Cell
Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
Main Objective: To evaluate progression-free survival in patients with unresectable renal cell carcinoma (RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.
- Trial name
- SOGUG-02-06 (NCT00496301)
- Testing
- Gemcitabine, Capecitabine and Sorafenib (6 cycles)
- Where
- 10 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib (Rucaparib…
- Trial name
- MITO25 (NCT03462212)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 7 sites in Italy
- Volunteers
- 290 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gastrointestinal Stromal Tumors
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this…
- Trial name
- NCT00976612
- Testing
- Nilotinib
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Asan Medical Center
Squamous Cell Carcinoma of the Head and Neck
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
The purpose of this study is to test a study drug called patritumab. Patritumab may work when combined with other medications that are approved in the UK for treating Squamous Cell Carcinoma of the Head and Neck (SCCHN), called…
- Trial name
- NCT02350712
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo
Lung Neoplasms, Lung Cancer, Nonsmall Cell
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery.
- Trial name
- NCT06530719
- Testing
- Osimertinib mesylate
- Volunteers
- 54 people
- Sponsor
- Jin Ying
Advanced Cancers
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
The goal of this research study is to learn if a type of light therapy can be used to help patients with advanced cancer who are having difficulty sleeping to sleep better.
- Trial name
- NCT01193530
- Testing
- Bright Light Therapy, Dim Red Light Therapy, Questionnaires
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Metastatic Colorectal Cancer
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for…
- Trial name
- NCT05593328
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 27 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cardiff Oncology
Pancreatic Cancer
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00079365
- Testing
- fluorouracil, gemcitabine hydrochloride, brachytherapy
- Where
- United States
- Sponsor
- University of South Florida
Multiple Myeloma Bone Lesions, Multiple Myeloma (MM)
Rehabilitation Management for Patients With Multiple Myeloma
Multiple myeloma (MM) is the second most common blood cancer. Bone involvement is very common in these patients: it is estimated that between 80% and 90% will develop bone lesions during the course of the disease.
- Trial name
- FKTMM2022 (NCT06838065)
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Recurrent Mantle Cell Lymphoma
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving CCI-779 together with rituximab works in treating patients with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT00109967
- Testing
- rituximab, temsirolimus
- Where
- 195 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Psoriasis
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI).
- Trial name
- NCT04571567
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Saakshi Khattri
Waldenstrom Macroglobulinemia
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
The purpose of this study is to evaluate the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated Waldenstrom macroglobulunemia (WM).
- Trial name
- THRiL for WM (NCT01779167)
- Testing
- Thalidomide, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Sarcoma
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00003054
- Testing
- paclitaxel
- Where
- 65 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Advanced Solid Tumors
Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours
The primary objective of this study was to determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid…
- Trial name
- NCT00692354
- Testing
- CHR-2797 (tosedostat)
- Volunteers
- 41 people
- Sponsor
- Chroma Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.